PDCD1LG2 and endometrial cancer: The high expression of the programmed cell death 1 (PD-1) receptor and its ligands, programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2), associated with the high mutational load of endometrial cancer dMMR/MSI-H make this subtype more sensitive to Immune Checkpoint Inhibitors (ICIs), particularly anti-PD-1 and anti-PD-L1 agents [10–12].